Timothy C. Brand, MD, FACS, Author at Grand Rounds in Urology

Timothy C. Brand, MD, FACS

Baptist Health Care

Pensacola, Florida

Timothy C. Brand, MD, FACS, is a urologist with Baptist Health Care in Pensacola, Florida. He was the Director of the Urology Residency at Madigan Army Medical Center in Tacoma, Washington, for 10 years, and has served as the Urology Consultant to the US Army Surgeon General. He specializes in robotic-assisted surgery for urologic malignancies. Education and research are his priorities. He was President of the Biomedical Engineering Honor Society at Tulane University in New Orleans, Louisiana, where he received his engineering degree. Additionally, he completed a Master’s of Science in Clinical Investigation, and has used this expertise to fuel a career in robotic surgery, resident education, and research. Dr. Brand has received numerous honors, including Board Certification in Urology, Society of Urologic Oncology membership, admission to the American College of Surgeons, a Meritorious Service Medal for the education of Army surgeons on the robotic surgical platform, and several award-winning research presentations. His research includes looking at standardizing curricula and certification for robotic-assisted surgery, surgical simulation, and assessing how oncologic outcomes after intervention for urologic malignancies are affected by pretreatment clinical characteristics.

Disclosures:

Talks by Timothy C. Brand, MD, FACS

There is a Role for Currently Available Biomarkers: Genomics in the Risk Stratification of Prostate Cancer

Posted by Timothy C. Brand, MD, FACS | Feb 2019

Timothy C. Brand, MD, FACS, argues that biomarkers and genomics have a role in the clinical decision-making process for individual patients with low- and favorable intermediate-risk prostate cancer. He also reviews the literature validating the risk stratification utility of recommended biomarkers.

Timothy C. Brand, MD, FACS

Baptist Health Care

Pensacola, Florida

Talks by Timothy C. Brand, MD, FACS

There is a Role for Currently Available Biomarkers: Genomics in the Risk Stratification of Prostate Cancer

Join the GRU Community

You have Successfully Subscribed!